Antitumor Activity of Novel Signal Transducer and Activator of Transcription 3 Inhibitors on Retinoblastoma > REFERENCE LIBRARY

본문 바로가기
커뮤니티

[EZ-Cytox] Antitumor Activity of Novel Signal Transducer and Activator of Transcription 3 Inhibitors on Retinob…

김상진
2022-01-28 08:34 2,797 1

본문

년도
2021
제품명
EZ-Cytox
학술지명
MOLECULAR PHARMACOLOGY

Signal transducer and activator of transcription 3 (STAT3) is a plausible therapeutic target in the treatment of retinoblastoma, the most common intraocular malignant tumor in children. STAT3, a transcription factor of several genes related to tumorigenesis, is activated in retinoblastoma tumors as well as other cancers. In this study, we investigated the structure-activity relationship of a library of STAT3 inhibitors, including a novel series of derivatives of the previously reported compound with a Michael acceptor (compound 1). We chose two novel STAT3 inhibitors, compounds 11 and 15, from the library based on their inhibitory effects on the phosphorylation and transcription activity of STAT3. These STAT3 inhibitors effectively suppressed the phosphorylation of STAT3 and inhibited the expression of STAT3-related genes CCND1CDKN1ABCL2BCL2L1BIRC5MYCMMP1MMP9, and VEGFA. Intraocularly administered STAT3 inhibitors decreased the degree of tumor formation in the vitreous cavity of BALB/c nude mice of an orthotopic transplantation model. It is noteworthy that compounds 11 and 15 did not induce in vitro and in vivo toxicity on retinal constituent cells and retinal tissues, respectively, despite their potent antitumor effects. We suggest that these novel STAT3 inhibitors be used in the treatment of retinoblastoma.

댓글목록1

김상진님의 댓글

김상진
2022-01-28 08:34
JournalImpactFactor(2019) : 3.664
카카오톡
이메일
견적/제품문의
샘플신청
게시판 전체검색